Method of Treating an Autoimmune Disease with Antagonistic CD40 Monoclonal Antibodies

A method of treating an autoimmune disease such as Sjögren's Syndrome is provided. The method comprises administration of an antibody or an antigen binding portion thereof that specifically binds an epitope of CD40 associated with antagonism. The antibody or the antigen binding portion thereof...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Price, Karen, Fura, Aberra, Aras, Urvi, Sharda, Nidhi, Girgis, Ihab, Ye, Ying, Struthers, Mary
Format: Patent
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator Price, Karen
Fura, Aberra
Aras, Urvi
Sharda, Nidhi
Girgis, Ihab
Ye, Ying
Struthers, Mary
description A method of treating an autoimmune disease such as Sjögren's Syndrome is provided. The method comprises administration of an antibody or an antigen binding portion thereof that specifically binds an epitope of CD40 associated with antagonism. The antibody or the antigen binding portion thereof does not exhibit CD40 agonist activity in either in vitro or in vivo preclinical testing. The antibody inhibits CD40L-induced signaling on DCs, resulting at least in part to reduced production of pro-inflammatory cytokines, and reduction of cell surface activation markers, CD86 and CD54. The antibodies can comprise an Fc region containing a mutation that reduces or eliminates binding to Fc receptors, reducing or eliminating Fc gamma receptor (FcγR)-mediated cross-linking or clustering.
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US2023331860A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US2023331860A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US2023331860A13</originalsourceid><addsrcrecordid>eNqNysEKglAQQFE3LaL6h4HWwdMX4Va0aOMqXcukow7ojPRG-v0I-oBWd3HuNqpLslE70B6qF6GxDIAC2WrK87wKQcGBMBC82UbIxHBQ4WDcQl6cHZQq2k4qOH2Rn9oxhX206XEKdPh1Fx1v1yq_n2jRhsKCLQlZUz8Sl3jv4_Tistj_d30AQG05LA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Method of Treating an Autoimmune Disease with Antagonistic CD40 Monoclonal Antibodies</title><source>esp@cenet</source><creator>Price, Karen ; Fura, Aberra ; Aras, Urvi ; Sharda, Nidhi ; Girgis, Ihab ; Ye, Ying ; Struthers, Mary</creator><creatorcontrib>Price, Karen ; Fura, Aberra ; Aras, Urvi ; Sharda, Nidhi ; Girgis, Ihab ; Ye, Ying ; Struthers, Mary</creatorcontrib><description>A method of treating an autoimmune disease such as Sjögren's Syndrome is provided. The method comprises administration of an antibody or an antigen binding portion thereof that specifically binds an epitope of CD40 associated with antagonism. The antibody or the antigen binding portion thereof does not exhibit CD40 agonist activity in either in vitro or in vivo preclinical testing. The antibody inhibits CD40L-induced signaling on DCs, resulting at least in part to reduced production of pro-inflammatory cytokines, and reduction of cell surface activation markers, CD86 and CD54. The antibodies can comprise an Fc region containing a mutation that reduces or eliminates binding to Fc receptors, reducing or eliminating Fc gamma receptor (FcγR)-mediated cross-linking or clustering.</description><language>eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2023</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20231019&amp;DB=EPODOC&amp;CC=US&amp;NR=2023331860A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,776,881,25543,76293</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20231019&amp;DB=EPODOC&amp;CC=US&amp;NR=2023331860A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Price, Karen</creatorcontrib><creatorcontrib>Fura, Aberra</creatorcontrib><creatorcontrib>Aras, Urvi</creatorcontrib><creatorcontrib>Sharda, Nidhi</creatorcontrib><creatorcontrib>Girgis, Ihab</creatorcontrib><creatorcontrib>Ye, Ying</creatorcontrib><creatorcontrib>Struthers, Mary</creatorcontrib><title>Method of Treating an Autoimmune Disease with Antagonistic CD40 Monoclonal Antibodies</title><description>A method of treating an autoimmune disease such as Sjögren's Syndrome is provided. The method comprises administration of an antibody or an antigen binding portion thereof that specifically binds an epitope of CD40 associated with antagonism. The antibody or the antigen binding portion thereof does not exhibit CD40 agonist activity in either in vitro or in vivo preclinical testing. The antibody inhibits CD40L-induced signaling on DCs, resulting at least in part to reduced production of pro-inflammatory cytokines, and reduction of cell surface activation markers, CD86 and CD54. The antibodies can comprise an Fc region containing a mutation that reduces or eliminates binding to Fc receptors, reducing or eliminating Fc gamma receptor (FcγR)-mediated cross-linking or clustering.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2023</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNysEKglAQQFE3LaL6h4HWwdMX4Va0aOMqXcukow7ojPRG-v0I-oBWd3HuNqpLslE70B6qF6GxDIAC2WrK87wKQcGBMBC82UbIxHBQ4WDcQl6cHZQq2k4qOH2Rn9oxhX206XEKdPh1Fx1v1yq_n2jRhsKCLQlZUz8Sl3jv4_Tistj_d30AQG05LA</recordid><startdate>20231019</startdate><enddate>20231019</enddate><creator>Price, Karen</creator><creator>Fura, Aberra</creator><creator>Aras, Urvi</creator><creator>Sharda, Nidhi</creator><creator>Girgis, Ihab</creator><creator>Ye, Ying</creator><creator>Struthers, Mary</creator><scope>EVB</scope></search><sort><creationdate>20231019</creationdate><title>Method of Treating an Autoimmune Disease with Antagonistic CD40 Monoclonal Antibodies</title><author>Price, Karen ; Fura, Aberra ; Aras, Urvi ; Sharda, Nidhi ; Girgis, Ihab ; Ye, Ying ; Struthers, Mary</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US2023331860A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2023</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>Price, Karen</creatorcontrib><creatorcontrib>Fura, Aberra</creatorcontrib><creatorcontrib>Aras, Urvi</creatorcontrib><creatorcontrib>Sharda, Nidhi</creatorcontrib><creatorcontrib>Girgis, Ihab</creatorcontrib><creatorcontrib>Ye, Ying</creatorcontrib><creatorcontrib>Struthers, Mary</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Price, Karen</au><au>Fura, Aberra</au><au>Aras, Urvi</au><au>Sharda, Nidhi</au><au>Girgis, Ihab</au><au>Ye, Ying</au><au>Struthers, Mary</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Method of Treating an Autoimmune Disease with Antagonistic CD40 Monoclonal Antibodies</title><date>2023-10-19</date><risdate>2023</risdate><abstract>A method of treating an autoimmune disease such as Sjögren's Syndrome is provided. The method comprises administration of an antibody or an antigen binding portion thereof that specifically binds an epitope of CD40 associated with antagonism. The antibody or the antigen binding portion thereof does not exhibit CD40 agonist activity in either in vitro or in vivo preclinical testing. The antibody inhibits CD40L-induced signaling on DCs, resulting at least in part to reduced production of pro-inflammatory cytokines, and reduction of cell surface activation markers, CD86 and CD54. The antibodies can comprise an Fc region containing a mutation that reduces or eliminates binding to Fc receptors, reducing or eliminating Fc gamma receptor (FcγR)-mediated cross-linking or clustering.</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language eng
recordid cdi_epo_espacenet_US2023331860A1
source esp@cenet
subjects CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title Method of Treating an Autoimmune Disease with Antagonistic CD40 Monoclonal Antibodies
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T07%3A22%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Price,%20Karen&rft.date=2023-10-19&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS2023331860A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true